Sartorius Stedim Biotech S.A. is a leading global provider in the biopharmaceutical sector, specializing in the design and manufacture of equipment and services to support the development, quality ass... Sartorius Stedim Biotech S.A. is a leading global provider in the biopharmaceutical sector, specializing in the design and manufacture of equipment and services to support the development, quality assurance, and production processes of biopharmaceuticals. The company's expertise lies in its comprehensive range of products that facilitate the entire drug manufacturing process, from upstream through downstream stages, which includes filtration, fermentation, purification, and fluid management technologies. Sartorius Stedim Biotech primarily serves industries involved in biotechnology and the pharmaceutical sector, making it instrumental in expediting the production of vaccines and other biologics. By offering highly advanced and efficient solutions, the company supports firms in achieving high quality and regulatory compliance. With headquarters in Aubagne, France, and operations extending globally, Sartorius Stedim Biotech plays a pivotal role in advancing the capabilities and efficiencies of drug production facilities worldwide, directly impacting the healthcare and life sciences landscape.
Sartorius Stedim Biotech's EU Taxonomy Data Preview
In 2024, Sartorius Stedim Biotech was subject to the Corporate Sustainability Reporting Directive (CSRD)'s requirements, which mandated the company to publish EU Taxonomy disclosures.
The company reported the eligibility and alignment of Turnover, Capital Expenditure (CAPEX) and Operating Expenditure (OPEX) with the EU Taxonomy, helping assess the extent to which its business activities align with Europe's environmental sustainability goals.
Sartorius Stedim Biotech has also provided an activity-level breakdown of its EU Taxonomy disclosures. This granular reporting enhances transparency around which economic activities of Sartorius Stedim Biotech are considered environmentally sustainable and contribute to at least one of the six environmental objectives defined under the EU Taxonomy framework.
Metric (tonnes)
2024
2023
2022
2021 - 2017
Total Taxonomy Aligned A1 Turnover
0000000
Copy/Paste is a PRO feature.
Copy/Paste is a PRO feature.
0000000
Total Taxonomy Eligible A Turnover
0000000
Copy/Paste is a PRO feature.
Copy/Paste is a PRO feature.
0000000
Total Taxonomy Non-Eligible B Turnover
Copy/Paste is a PRO feature.
a
Copy/Paste is a PRO feature.
Copy/Paste is a PRO feature.
0000000
1.2 CE - Manufacture of electrical and electronic equipment
Copy/Paste is a PRO feature.
a
Copy/Paste is a PRO feature.
Copy/Paste is a PRO feature.
0000000
Metric (tonnes)
2024
2023
2022
2021 - 2017
Total Taxonomy Aligned A1 Opex
0000000
Copy/Paste is a PRO feature.
Copy/Paste is a PRO feature.
0000000
Total Taxonomy Eligible A Opex
0000000
Copy/Paste is a PRO feature.
Copy/Paste is a PRO feature.
0000000
Total Taxonomy Non-Eligible B Opex
Copy/Paste is a PRO feature.
a
Copy/Paste is a PRO feature.
Copy/Paste is a PRO feature.
0000000
7.7 CCM/CCA - Acquisition and ownership of buildings
Copy/Paste is a PRO feature.
a
Copy/Paste is a PRO feature.
Copy/Paste is a PRO feature.
0000000
Metric (tonnes)
2024
2023
2022
2021 - 2017
Total Taxonomy Aligned A1 Capex
0000000
Copy/Paste is a PRO feature.
Copy/Paste is a PRO feature.
0000000
Total Taxonomy Eligible A Capex
0000000
Copy/Paste is a PRO feature.
Copy/Paste is a PRO feature.
0000000
Total Taxonomy Non-Eligible B Capex
Copy/Paste is a PRO feature.
a
Copy/Paste is a PRO feature.
Copy/Paste is a PRO feature.
0000000
7.7 CCM/CCA - Acquisition and ownership of buildings
Copy/Paste is a PRO feature.
a
Copy/Paste is a PRO feature.
Copy/Paste is a PRO feature.
0000000
Limited Data Preview
You are viewing a limited preview of Sartorius Stedim Biotech’s EU Taxonomy dataset. The full dataset, available for download, includes eligibility and alignment metrics for turnover, CAPEX, and OPEX across all EU Taxonomy categories (A1, A2, A, B, and A+B), at both aggregate and activity level, with historical coverage back to undefined.
Access Datasets, Disclosures, and Sources
pro
Remove manual data sourcing from your workflow. Subscribe to Tracenable Pro to get credits for accessing and exporting datasets and disclosures across 8,500+ companies with 10+ years of historical coverage.
Used by 1,000+ teams in finance, climate, and research
Verified Sources Behind Sartorius Stedim Biotech’s EU Taxonomy Data
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Sartorius Stedim Biotech’s data sources below and access millions more through our Disclosure Search.
a. Sartorius Stedim Biotech's Universal Registration Document (URD) 2024
Insights into Sartorius Stedim Biotech's Revenues from Sustainable Activities
In 2024, Sartorius Stedim Biotech reported EU Taxonomy-eligible revenues of EUR 750.10 million, representing 27% of its total turnover. Of this amount, EUR 26.20 million of Sartorius Stedim Biotech's revenues was classified as EU Taxonomy-aligned, indicating that 1% of the revenue-generating activities undertaken by the company substantially contribute to one or more of the six environmental objectives, meet the Do No Significant Harm (DNSH) criteria, and comply with the Minimum Social Safeguards (MSS).a
How much of Sartorius Stedim Biotech's revenue is eligible under the EU Taxonomy?
In 2024, Sartorius Stedim Biotech reported that EUR 750.10 million of its revenue was eligible under the EU Taxonomy, representing 27% of the company's total turnover. Of this amount, EUR 26.20 million (1% of total revenue) was classified as Taxonomy-aligned. This means that 26% of Sartorius Stedim Biotech's revenue is eligible but not aligned, indicating that these activities did not meet the technical screening criteria, failed to comply with the Do No Significant Harm (DNSH) requirements, or lacked evidence of meeting the Minimum Safeguards.a
How much of Sartorius Stedim Biotech's eligible revenue is aligned with the EU Taxonomy?
In 2024, Sartorius Stedim Biotech reported that EUR 26.20 million of its revenue was aligned under the EU Taxonomy, representing 1% of its total turnover.a
This low alignment highlights either a limited focus on green activities or early-stage adoption of sustainability frameworks, underscoring opportunities for further alignment with EU climate objectives.
Sartorius Stedim Biotech's Contribution to Environmental Objectives
Total Taxonomy Aligned A1 Turnover
Total Taxonomy Eligible but Not Aligned A2 Turnover
How is Sartorius Stedim Biotech's taxonomy-aligned revenue distributed across the EU environmental objectives?
In 2024, Sartorius Stedim Biotech reported that its taxonomy-aligned revenue was distributed across the following EU environmental objectivesa:
Climate Change Mitigation: 0%
Climate Change Adaptation: 0%
Sustainable Use and Protection of Water and Marine Resources: 0%
Transition to a Circular Economy: 1%
Pollution Prevention and Control: 0%
Protection and restoration of biodiversity and ecosystems: 0%
How much revenue does Sartorius Stedim Biotech earn from selling climate-related solutions ?
In 2024, Sartorius Stedim Biotech reported that EUR 0 of its total revenue was associated with activities contributing to the EU taxonomy climate-related objectives (Climate Change Mitigation and Climate Change Adaptation). This accounted for 0% of the company's total revenue,indicating that Sartorius Stedim Biotechhas limited exposureon solutions that support climate action through its commercial activities.a
Insights into Sartorius Stedim Biotech's CAPEX from Sustainable Activities
In 2024, Sartorius Stedim Biotech reported EU Taxonomy-eligible CAPEX of EUR 339.30 million,representing 72% of its total CAPEX. Of this amount, EUR 72.00 million of Sartorius Stedim Biotech's CAPEX was classified as EU Taxonomy-aligned, indicating that 15% of the company's investments were directed toward economic activities that substantially contribute to one or more of the six environmental objectives, meet the Do No Significant Harm (DNSH) criteria, and comply with the Minimum Social Safeguards (MSS).a
How much of Sartorius Stedim Biotech's capital expenditure (CAPEX) is eligible under the EU Taxonomy?
In 2024, Sartorius Stedim Biotech reported that EUR 339.30 million of its capital expenditure (CAPEX) was eligible under the EU Taxonomy, representing 72% of the company's total CAPEX. Of this amount, EUR 72.00 million (15% of total CAPEX) was classified as Taxonomy-aligned. This means that 57% of Sartorius Stedim Biotech's CAPEX is eligible but not aligned, indicating that these investments either did not meet the technical screening criteria, failed to comply with the Do No Significant Harm (DNSH) requirements, or lacked evidence of meeting the Minimum Safeguards (MSS).a
How much of Sartorius Stedim Biotech's eligible CAPEX is aligned with the EU Taxonomy?
In 2024, Sartorius Stedim Biotech reported that EUR 72.00 million of its CAPEX was aligned under the EU Taxonomy, representing 15% of its total capital investment.a
This moderate level of alignment indicates that Sartorius Stedim Biotech is beginning to transition its capital allocation toward greener investments, but still retains substantial opportunities for further alignment with sustainability goals.
Sartorius Stedim Biotech's Contribution to Environmental Objectives
Total Taxonomy Aligned A1 Capex
Total Taxonomy Eligible but Not Aligned A2 Capex
How is Sartorius Stedim Biotech's taxonomy-aligned CAPEX distributed across the EU environmental objectives?
In 2024, Sartorius Stedim Biotech reported that its taxonomy-aligned capital expenditure (CAPEX) was distributed across the following EU environmental objectivesa:
Climate Change Mitigation: 15%
Climate Change Adaptation: 0%
Sustainable Use and Protection of Water and Marine Resources: 0%
Transition to a Circular Economy: 0%
Pollution Prevention and Control: 0%
Protection and restoration of biodiversity and ecosystems: 0%
How much Sartorius Stedim Biotech is investing in climate-related solutions?
In 2024, Sartorius Stedim Biotech allocated EUR 70.35 million of its CAPEX to activities contributing to the EU Taxonomy's climate-related objectives (Climate Change Mitigation and Climate Change Adaptation). This represented 15% of the company's total capital expenditure,indicating that Sartorius Stedim Biotechis moderately allocating capital toward climate-aligned initiatives, while maintaining a diversified investment portfolio.a
Insights into Sartorius Stedim Biotech's OPEX from Sustainable Activities
In 2024, Sartorius Stedim Biotech reported EU Taxonomy-eligible OPEX of EUR 34.40 million,representing 30% of its total operating expenses (OPEX). Of this amount, EUR 1.60 million of Sartorius Stedim Biotech's OPEX was classified as EU Taxonomy-aligned, indicating that 1% of the company's operating expenses were directed toward economic activities that substantially contribute to one or more of the six environmental objectives, meet the Do No Significant Harm (DNSH) criteria, and comply with the Minimum Social Safeguards (MSS).a
How much of Sartorius Stedim Biotech's operational expenditure (OPEX) is eligible under the EU Taxonomy?
In 2024, Sartorius Stedim Biotech reported that EUR 34.40 million of its operational expenditure (OPEX) was eligible under the EU Taxonomy, representing 30% of the company's total OPEX. Of this amount, EUR 1.60 million (1% of total OPEX) was classified as Taxonomy-aligned. This means that 28% of Sartorius Stedim Biotech's OPEX is eligible but not aligned, indicating that these expenditures either did not meet the technical screening criteria, failed to comply with the Do No Significant Harm (DNSH) requirements, or lacked evidence of meeting the Minimum Safeguards (MSS).a
How much of Sartorius Stedim Biotech's eligible OPEX is aligned with the EU Taxonomy?
In 2024, Sartorius Stedim Biotech reported that EUR 1.60 million of its OPEX was aligned under the EU Taxonomy, representing 1% of its total operational expenditure.a
This low alignment reflects limited operational focus on green activities, suggesting that sustainability considerations have yet to be fully integrated into core operating processes.
Sartorius Stedim Biotech's Contribution to Environmental Objectives
Total Taxonomy Aligned A1 Opex
Total Taxonomy Eligible but Not Aligned A2 Opex
How is Sartorius Stedim Biotech's taxonomy-aligned OPEX distributed across the EU environmental objectives?
In 2024, Sartorius Stedim Biotech reported that its taxonomy-aligned operational expenditure (OPEX) was distributed across the following EU environmental objectivesa:
Climate Change Mitigation: 1%
Climate Change Adaptation: 0%
Sustainable Use and Protection of Water and Marine Resources: 0%
Transition to a Circular Economy: 0%
Pollution Prevention and Control: 0%
Protection and restoration of biodiversity and ecosystems: 0%
How much of Sartorius Stedim Biotech's operational budget supports climate-related solutions?
In 2024, Sartorius Stedim Biotech allocated EUR 1.16 million of its OPEX to activities contributing to the EU Taxonomy's climate-related objectives (Climate Change Mitigation and Climate Change Adaptation). This represented 1% of the company's total OPEX,indicating that Sartorius Stedim Biotechhas only a limited share of operational expenditure aligned with climate goals, signaling early-stage or minimal integration of climate objectives into its routine activities.a
Want Full Access to Sartorius Stedim Biotech's EU Taxonomy Dataset?
a
a
a
a
a